Welcome to our dedicated page for Cosmo Pharmaceuticals Nv news (Ticker: CMOPF), a resource for investors and traders seeking the latest updates and insights on Cosmo Pharmaceuticals Nv stock.
Cosmo Pharmaceuticals N.V. reports news across its life sciences business, including MedTech AI, dermatology, gastrointestinal disease programs, and contract development and manufacturing. Company updates frequently cover the GI Genius™ platform and real-time medical AI for endoscopy, dermatology assets such as Clascoterone 5% topical solution and Winlevi®, and gastroenterology research programs in bile acid diarrhea and distal ulcerative colitis.
Recurring disclosures also include annual results, recurring revenue trends, dividend actions, AGM voting outcomes, ESG reporting, board and remuneration matters, and capital-structure authorizations. Partnership and R&D collaboration announcements describe how Cosmo extends AI-enabled medical technology into additional clinical applications while maintaining a broader portfolio of pharmaceutical and CDMO activities.
Cosmo (CMOPF) completed enrolment in its Phase II trial of rifamycin enema for distal ulcerative colitis and ulcerative proctitis. 77 patients were enrolled across 24 European sites. The bio-adhesive, locally acting formulation targets inflamed distal colon and rectum. Topline results are expected in fall 2026.
Cosmo Pharmaceuticals (OTC: CMOPF) reported positive 12-month Phase III results for Clascoterone 5% topical solution in men with mild-to-moderate androgenetic alopecia. The program enrolled 1,465 subjects across 51 centers. Continuous treatment produced a statistically significant 2.39x improvement in Target Area Hair Count versus patients switched to vehicle, safety was comparable to vehicle, and patient satisfaction improved +24.5%. NDA and MAA work is underway with a U.S. filing planned for early 2027.
Cosmo Pharmaceuticals (CMOPF) reported that shareholders approved all items at the Ordinary Annual General Meeting on April 10, 2026.
10,354,065 ordinary shares were represented, equal to 59.02% of outstanding ordinary shares. Shareholders approved a €2.10 per share dividend; ex-dividend date is 24 April 2026 and payment date is 11 May 2026.
Cosmo (OTC: CMOPF) will present at NVIDIA GTC 2026 in San Jose, March 16–19. On March 19 at 10:00 CET Cosmo delivers a session titled "Engineering Medical Grade Platforms for Real Time AI" featuring MedTech AI leaders Nhan Ngo Dinh and Pietro Salvagnini.
The talk highlights Cosmo's real‑time clinical AI systems such as GI Genius and its use of NVIDIA accelerated computing for intra‑procedure detection, decision support, and workflow optimization.
Cosmo (OTC:CMOPF) has convened its Ordinary Annual General Meeting for 10 April 2026 in Amsterdam. Key agenda items include the Board report for 2025, appropriation of full-year 2025 results, a proposed distribution of €2.10 per share, a corporate name change to Cosmo N.V., director reappointments, adoption of remuneration policy, and authorisations to issue new ordinary and preferred shares.
Complete convening notice, explanatory notes and proxy, plus the Annual Report 2025 and ESG Report 2025, are available on the company website.
Cosmo Pharmaceuticals (OTC: CMOPF) reported FY2025 total revenue €104.2M with recurring revenues €88.1M (+15% YoY, 85% of total), EBITDA €9.5M (above guidance), cash, equivalents and investments €128.3M and no financial debt. The Board proposes a €2.10 dividend. 2026 guidance: recurring revenues €98–102M, total revenues €105–110M, EBITDA €10.5–13.5M and year-end cash ~€200M.
Cosmo (OTC:CMOPF) announced a strategic R&D collaboration with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an AI-based computer-aided detection (CADe) system for early neoplasia in Barrett's esophagus.
The program will curate large imaging datasets, train AI algorithms, run structured clinical validation, and pursue industrialization and regulatory pathways for integration into the GI Genius platform.
Cosmo Pharmaceuticals (OTC:CMOPF) announced management will attend three investor conferences in March–May 2026 with scheduled one-on-one investor meetings.
Key dates: UBS European Healthcare Conference (London) on 4 March 2026; Jefferies Biotech Summit (Miami) on 11 March 2026; TP ICAP Healthcare Conference (Paris) on 7 May 2026. Investors may request meetings via investor.relations@cosmohc.com.
Cosmo Pharmaceuticals (OTC:CMOPF) completed a private placement of 937,086 treasury shares to Capital Group's SMALLCAP World Fund on February 3, 2026, representing ~5.3% of outstanding shares. The sale used existing treasury shares and therefore does not dilute existing shareholders; shares are fungible and rank pari passu. Cosmo said the transaction strengthens its shareholder base, enhances financial flexibility, and supports investment in MedTech AI, dermatology, gastroenterology, and CDMO. Cosmo will file required major shareholding notifications with SIX Swiss Exchange.
Summary not available.